Build­ing on its reti­nal dis­ease ex­per­tise, Re­gen­eron signs eye-fo­cused gene ther­a­py pact with Ger­man biotech

Re­gen­eron beefed up its gene ther­a­py ca­pa­bil­i­ties Wednes­day, sign­ing a new deal with the Ger­man biotech Vi­Gen­eron.

The sim­i­lar­ly named — but un­re­lat­ed — com­pa­nies an­nounced the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER